SAB Biotherapeutics, Inc.
Company Stats
- Market Cap
- $288.4M
- as of Sep 30, 2026
- Shares Outstanding
- 91.0M
- Free Float
- 67.9%
Income Statement
- Revenue
- $0
- Operating Income
- -$49.0M
- Net Income
- $13.3M
- EBITDA
- -$46.0M
Cash Flow
- Free Cash Flow
- -$45.7M
- FCF Yield
- -15.8%
- Owner FCF Yield
- -17.7%
Balance Sheet
- Cash & Equivalents
- $10.5M
Returns & Capital
- SBC, 3Y Avg
- $3.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $0 | -$45.7M | — |
| FY2024 | $1.3M | -$34.6M | -2618.6% |
| FY2023 | $2.2M | -$25.3M | -1130.7% |
| FY2022 | $23.9M | -$25.6M | -107.2% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 14, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.